MétaCan
Menu
Back to cohort
Record W2247744690

A monoclonal antibody targeting melanoma-associated chondroitin sulfate proteoglycan demonstrates antitumor activity in human melanoma, ovarian and breast cancer models.

2007· article· en· W2247744690 on OpenAlexaff
Ashwani Gupta, Alison Ferry, Daad Sayegh, Luis da Cruz, Ningping Feng, Susan Hahn, Daniel S. Pereira, Helen Findlay, David Young

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicGlycosylation and Glycoproteins Research
Canadian institutionsArius3D (Canada)
Fundersnot available
KeywordsOvarian cancerMelanomaCancer researchBreast cancerChondroitin sulfate proteoglycanCancerMedicineMetastasisImmunologyChondroitin sulfateInternal medicineGlycosaminoglycan
DOInot available

Abstract

fetched live from OpenAlex

B40 Melanoma-associated chondroitin sulfate proteoglycan (MCSP) is a glycoprotein-proteoglycan complex present on the surface of melanoma cells, and has been reported to have a role in cancer progression by enhancing adhesion and invasion of melanoma cells through multiple mechanisms. MCSP, also known as the high molecular weight-melanoma associated antigen (HMW-MAA), has been shown recently to be expressed in human breast cancer stem cells.
 AR11BD-2E11-2, a monoclonal antibody that targets MCSP was discovered using the FunctionFIRST™ platform. Briefly, human breast cancer tissue was used to immunize mice and hybridomas were screened for cytotoxicity against a variety of cancer cell lines. For example, AR11BD-2E11-2 showed cytotoxicity in breast and ovarian cancer cell lines. When AR11BD-2E11-2 was evaluated in vivo, anti-tumor activity was apparent not only in breast and ovarian tumor models, but in a model of human melanoma as well. In the MCF-7 xenograft breast cancer model, AR11BD-2E11-2 was shown to significantly reduce tumor volume by 79% compared to isotype control treated mice (p=0.048), as well as confer a significant survival benefit (p=0.03). A 49% (p=0.0004) reduction in tumor volume was also observed in a second breast cancer xenograft model MDA-MB-231. In an OVCAR-3 xenograft ovarian cancer model, the increase in body weight due to ascites can be used as a marker of disease progression. In this model, the mice in the control treated group showed a 60% tumor-related weight gain, while the AR11BD-2E11-2 treated mice showed a significantly lower weight gain of 40% (p=0.03) corresponding to decreased ascites formation, as well as having a significantly longer mean survival time (p

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.316
Teacher spread0.296 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicGlycosylation and Glycoproteins ResearchFrench-language works237,207